RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Share this content:

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Sponsor and Collaborators     
University of Utah
Novartis

Contacts
Marlene Mitchell, RN     
801-587-4779     
marlene.mitchell@hci.utah.edu

Cindy Davidson, APRN     
801-587-5581     
cynthia.davidson@hci.utah.edu

Investigator    
Sunil Sharma, MD     Huntsman Cancer Institute

ClinicalTrials.gov Identifier
NCT01047293

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs